CJC-1295 with DAC: reported timelines in the literature
A research-supply review of CJC-1295 with DAC (Drug Affinity Complex), covering its classification as a GHRH analogue, the GH-IGF-1 axis it is studied against, and the reported timelines from the available literature.
CJC-1295 with DAC is a growth hormone-releasing hormone (GHRH) analogue modified with a Drug Affinity Complex, placing it in the same research class as sermorelin, tesamorelin, and CJC-1295 without DAC [1]. It is handled in the literature as a research compound rather than an approved therapeutic, and the reported timelines associated with it come almost entirely from small, early-stage or non-clinical work rather than from large controlled trials. The evidence block used for this page does not supply a sequence, molecular formula, or molecular weight for the compound, so none are stated here.
The work centres on the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis, the endocrine pathway that GHRH analogues are studied for their capacity to modulate [1].
Research Studies
CJC-1295 with DAC and the GH-IGF-1 axis in performance-enhancing peptide surveys
Survey work on performance-enhancing peptides marketed as research compounds lists CJC-1295 with DAC among the GHRH analogues most commonly encountered both in clinical practice and in online self-administration protocols [1]. The same survey groups it alongside GHRP-2, GHRP-6, hexarelin, ipamorelin, the GH fragment AOD9604 (hGH 176-191), and an IGF-1 analogue, all of which are described as unregulated peptides intended to modulate the GH-IGF-1 axis [1]. This is a classification and prevalence finding, not a timeline finding: the survey establishes where the compound sits in the research landscape, not how long any effect takes to appear.
CJC-1295 with DAC and the 12-week HIV-associated visceral obesity protocol
The most concrete timeline in the evidence block comes from a registered Phase 2 study of CJC 1295 in patients with HIV-associated visceral obesity [6]. That study was designed as a multicentre, randomised, placebo-controlled, double-blind trial with a 12-week treatment period followed by a 6-week follow-up period after treatment ended [6]. Participants were to be randomly assigned to low-dose CJC 1295, high-dose CJC 1295, or placebo, with the stated objective of assessing and comparing efficacy, pharmacokinetics, safety, and tolerability in that population [6].
Two points of care are needed here. First, the registry record describes the planned design; it does not report outcomes, and no result data are available in the evidence block. Second, the record names the intervention as CJC 1295, and the evidence block does not state whether the DAC-modified form was the material used. The 12-week treatment window and 6-week follow-up should therefore be read as the protocol timeline for a CJC 1295 study in an HIV-associated visceral obesity population, not as a confirmed timeline for the DAC conjugate specifically.
| Study element | Reported detail |
|---|---|
| Design | Multicentre, randomised, placebo-controlled, double-blind, Phase 2 [6] |
| Population | Patients with HIV-associated visceral obesity [6] |
| Arms | Low-dose CJC 1295, high-dose CJC 1295, placebo [6] |
| Treatment period | 12 weeks [6] |
| Follow-up | 6 weeks after treatment ends [6] |
| Stated objectives | Efficacy, pharmacokinetics, safety, tolerability [6] |
CJC-1295 with DAC and purity variability in gray-market preparations
An evaluation of research-grade peptides marketed directly to consumers examined purity, measured abundance, and endotoxin burden using a large publicly available independent testing dataset, and compared cost against compounded and FDA-approved alternatives [2]. The dataset covered 6,441 samples [2]. The framing of that work is that peptides are a rapidly expanding drug class with a parallel, largely unregulated gray market sold directly to consumers for self-administration, and that use of gray-market peptides has grown substantially [2].
For timeline purposes this matters indirectly. Where a preparation's measured abundance differs from its label, any timeline reported for the labelled compound may not describe the material actually present in a given vial. The evidence block does not break the dataset down by individual compound, so no CJC-1295-with-DAC-specific purity figure can be stated here.
CJC-1295 with DAC and the gerontological peptide literature
A narrative review of therapeutic peptides in gerontology examined mechanisms, clinical applications, evidence base, and safety profiles for peptides with demonstrated or potential applications in healthy aging and age-related conditions, drawing on PubMed, Scopus, and regulatory databases including the FDA and WADA [3]. The review frames peptide therapeutics as targeting hallmarks of aging such as metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline [3].
This is a review-level source. It supports the general proposition that hormonal decline is a target of interest in peptide research; it does not supply a timeline for CJC-1295 with DAC, and no such timeline is attributed to it here.
CJC-1295 with DAC and musculoskeletal and athletic-performance peptide reviews
Several reviews in the evidence block address approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance, describing peptides as short amino acid chains occupying a pharmacological niche between small-molecule drugs and large proteins, and noting that a parallel gray market of unapproved compounds operates largely outside regulatory oversight [4][5][9]. Related work notes that injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair, and performance enhancement, while clinical adoption has outpaced high-quality evidence and regulatory consensus [8].
These sources are relevant to CJC-1295 with DAC only at the class level. They establish the regulatory and evidentiary context in which timelines are reported, and they do not provide compound-specific timeline data.
CJC-1295 with DAC and peptide-supplement marketing claims
Work on peptide supplements and their therapeutic applications in sports medicine reports that the peptide supplement market has grown rapidly on marketing claims of enhanced performance and accelerated recovery from musculoskeletal injury, and that these products are often perceived as low risk despite an absence of efficacy or safety data [7]. A critical review of peptide and peptide-analogue use in recreational and professional sport and bodybuilding describes a shift from anabolic-androgenic steroids toward peptides and peptide analogues marketed as more selective and ostensibly safer alternatives, including growth hormone secretagogues such as ipamorelin [10].
Neither source provides a timeline for CJC-1295 with DAC. They are included because they describe how timelines circulate: claims of accelerated recovery are marketing claims, and the reviews report that the underlying evidence base is thin.
CJC-1295 with DAC and the limits of the available timeline evidence
Pulling the threads together, the evidence block supports exactly one structured timeline for a CJC 1295 study: a 12-week treatment period with a 6-week follow-up in HIV-associated visceral obesity, with no outcomes reported [6]. Everything else is class-level context. The GH-IGF-1 survey establishes that CJC-1295 with DAC is among the GHRH analogues encountered in self-administration protocols [1]. The purity evaluation establishes that gray-market preparations vary in measured abundance and carry endotoxin burden considerations [2]. The review literature establishes that clinical adoption has outpaced high-quality evidence [3][4][5][7][8][9][10].
Where the evidence block is silent, this page is silent. No animal-only or in vitro timeline data for CJC-1295 with DAC appear in the sources provided, and none are asserted. No human dose, administration schedule, or expected onset is given, because the evidence block does not supply one.
If you are reading this for personal health reasons
The material described on this page is sold for laboratory research use only, and we do not provide dosing, administration, or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician rather than relying on catalogue or review content. Nothing here should be read as a recommendation, a protocol, or a promise of any outcome.
Sources
- [1] The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration — https://europepmc.org/article/PMC/PMC13322892
- [2] Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance — https://doi.org/10.20944/preprints202604.1748.v1
- [3] Therapeutic peptides in gerontology: mechanisms and applications for healthy aging — https://europepmc.org/article/PMC/PMC13095733
- [4] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v3
- [5] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://doi.org/10.20944/preprints202512.1011.v1
- [6] A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity — https://clinicaltrials.gov/study/NCT00267527
- [7] Peptide Supplements and Their Therapeutic Applications in Sports Medicine — https://pubmed.ncbi.nlm.nih.gov/42578445/
- [8] Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications — https://pubmed.ncbi.nlm.nih.gov/42160466/
- [9] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — https://pubmed.ncbi.nlm.nih.gov/41966639/
- [10] A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review — https://pubmed.ncbi.nlm.nih.gov/41880199/